TRINETRA › Sectors › Healthcare
Thyrocare Technologies Limited (THYROCARE) — share price, P/E and fundamentals
Thyrocare Technologies Limited (NSE: THYROCARE) closed at ₹456.30 on 30 Oct 2026, +10.1% over one year, against a 52-week range of ₹342.55 – ₹662.00.
In the quarter ended 30 Sept 2026 (consolidated, filed 29 Oct 2026) it reported revenue of ₹271 cr and net profit of ₹16 cr, a 5.9% net margin; revenue grew 25.1% and profit fell 47.3% year on year.
On four consecutive filed quarters its trailing P/E is 50.4; since 24 Apr 2025 its own P/E has ranged from 40.3 to 93.0 (median 54.8), and today's reading is higher than 30% of those 375 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 11.5%, ROCE 22.4%, debt-to-equity 0.00, Piotroski F-score 7 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 14% of 63 sector peers; PBT margin higher than 22% of 63 sector peers; ROE higher than 35% of 63 sector peers.
Key figures
| Last close | ₹456.30 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -19.5% / +15.5% / +10.1% |
| 52-week low – high | ₹342.55 – ₹662.00 |
| Market capitalisation | ₹7,263 cr |
| Trailing P/E | 50.4 |
| Price / book | 13.12 |
| EV / EBITDA | 27.3 |
| Earnings yield | 2.0% |
| TTM EPS | ₹9.06 |
| TTM net profit | ₹144 cr |
| Quarter revenue | ₹271 cr |
| Quarter net profit | ₹16 cr |
| Net margin | 5.9% |
| Revenue growth (YoY) | +25.1% |
| Profit growth (YoY) | -47.3% |
| Return on equity | 11.5% |
| ROCE | 22.4% |
| Debt / equity | 0.00 |
| Current ratio | 3.40 |
| Free cash flow | ₹100 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹15.8 cr |
Against Healthcare peers
| Metric | THYROCARE | Peer median | Percentile |
|---|---|---|---|
| Net margin | 5.87 | 12.89 | 14 |
| PBT margin | 12.13 | 17.68 | 22 |
| ROE | 11.48 | 13.87 | 35 |
| ROCE | 22.42 | 16.59 | 71 |
| Debt / equity | 0.00 | 0.11 | 12 |
| FCF margin | 19.48 | -0.87 | 86 |
| Cash conversion | 1.99 | 1.25 | 84 |
| Trailing P/E | 50.36 | 43.07 | 56 |
Questions
What is the P/E ratio of Thyrocare Technologies Limited?
Thyrocare Technologies Limited's trailing P/E is 50.4, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 24 Apr 2025 its P/E has ranged 40.3–93.0.
What were Thyrocare Technologies Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Thyrocare Technologies Limited reported revenue of ₹271 cr and net profit of ₹16 cr (consolidated), filed with the exchange on 29 Oct 2026.
What is Thyrocare Technologies Limited's ROE?
Return on equity is 11.5% based on the balance sheet dated 30 Sept 2026.
Does Thyrocare Technologies Limited have debt?
Debt-to-equity is 0.00 on the balance sheet dated 30 Sept 2026.
What is THYROCARE's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, THYROCARE traded between ₹342.55 and ₹662.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.